Literature DB >> 8770918

Hypothalamic and pituitary leukemia inhibitory factor gene expression in vivo: a novel endotoxin-inducible neuro-endocrine interface.

Z Wang1, S G Ren, S Melmed.   

Abstract

We have recently shown expression of leukemia inhibitory factor (LIF) in human fetal pituitary tissue and its in vitro induction of POMC transcription. We now use qualitative and semiquantitative RT-PCR to demonstrate that LIF and LIF-receptor (LIF-R) are constitutively expressed in the normal mouse hypothalamus and pituitary. Hypothalamic and pituitary LIF and LIF-R are significantly induced (up to 6- and 4-fold, respectively) in vivo in response to lipopolysaccharide endotoxin (LPS) administered to B6D2F1 and C57BL/6 mice. In contrast to the nearly exclusive expression of matrix-associated LIF messenger RNA (mRNA) in control hypothalamus and pituitary, both diffusible and matrix-associated LIF mRNA alternate transcripts are induced by LPS. Furthermore, the time course of peripheral ACTH-response to LPS peaks at 60 min, whereas hypothalamic LIF mRNA increase occurs at 30 min and pituitary LIF induction occurs at 60 min. These results show that mLIF is a novel LPS-inducible proinflammatory neuroendocrine cytokine and the alternatively spliced diffusible LIF may play a paracrine role in activating pituitary ACTH secretion in synergy with hypothalamic CRH, implying a mechanism for central nervous system cytokine responses to immune signals.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8770918     DOI: 10.1210/endo.137.7.8770918

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  17 in total

Review 1.  The central role of SOCS-3 in integrating the neuro-immunoendocrine interface.

Authors:  C J Auernhammer; S Melmed
Journal:  J Clin Invest       Date:  2001-12       Impact factor: 14.808

Review 2.  gp130 cytokine signaling in the pituitary gland: a paradigm for cytokine-neuro-endocrine pathways.

Authors:  E Arzt
Journal:  J Clin Invest       Date:  2001-12       Impact factor: 14.808

Review 3.  Series introduction. The immuno-neuroendocrine interface.

Authors:  S Melmed
Journal:  J Clin Invest       Date:  2001-12       Impact factor: 14.808

Review 4.  Hypothalamic mechanisms in cachexia.

Authors:  Aaron J Grossberg; Jarrad M Scarlett; Daniel L Marks
Journal:  Physiol Behav       Date:  2010-03-25

5.  Leukemia inhibitory factor induces differentiation of pituitary corticotroph function: an immuno-neuroendocrine phenotypic switch.

Authors:  B Stefana; D W Ray; S Melmed
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-29       Impact factor: 11.205

6.  Effects of leukemia inhibitory receptor gene mutations on human hypothalamo-pituitary-adrenal function.

Authors:  Tulay Guran; Omer Guran; Cem Paketci; Osman Kipoglu; Irfan Firat; Serap Turan; Zeynep Atay; Belma Haliloglu; Abdullah Bereket
Journal:  Pituitary       Date:  2015-08       Impact factor: 4.107

7.  Direct regulation of pituitary proopiomelanocortin by STAT3 provides a novel mechanism for immuno-neuroendocrine interfacing.

Authors:  C Bousquet; M C Zatelli; S Melmed
Journal:  J Clin Invest       Date:  2000-12       Impact factor: 14.808

8.  Inhibitory roles for SHP-1 and SOCS-3 following pituitary proopiomelanocortin induction by leukemia inhibitory factor.

Authors:  C Bousquet; C Susini; S Melmed
Journal:  J Clin Invest       Date:  1999-11       Impact factor: 14.808

9.  Autoregulation of pituitary corticotroph SOCS-3 expression: characterization of the murine SOCS-3 promoter.

Authors:  C J Auernhammer; C Bousquet; S Melmed
Journal:  Proc Natl Acad Sci U S A       Date:  1999-06-08       Impact factor: 11.205

10.  Arcuate nucleus proopiomelanocortin neurons mediate the acute anorectic actions of leukemia inhibitory factor via gp130.

Authors:  Aaron J Grossberg; Jarrad M Scarlett; XinXia Zhu; Darren D Bowe; Ayesha K Batra; Theodore P Braun; Daniel L Marks
Journal:  Endocrinology       Date:  2009-12-16       Impact factor: 4.736

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.